Geneva, Switzerland - June 30, 2025 - Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Geneva, Switzerland, September 19, 2024-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Geneva, Switzerland, November 11, 2024-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Addex Therapeutics’ attempt to expand use of dipraglurant into muscle spasms has stumbled at the first hurdle. A phase 2a clinical trial of the mGluR5 negative allosteric modulator has delivered ...
Geneva, Switzerland, April 23, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Addex Therapeutics (ADXN) is scheduled to report earnings on November 22, 2024. The last reported earnings were for reported on September 30, 2024 for Q2.
On Wednesday, Addex Therapeutics (NASDAQ:ADXN) maintained its Buy rating and $30.00 stock price target from H.C. Wainwright. The firm's positive outlook follows Addex's recent business update and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results